Comparing the current results to its competitors, Scisparc Ltd reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Scisparc Ltd's competitors' average revenue growth of 46.33 %, achieved in the same quarter.
Scisparc Ltd's Comment on Competition and Industry Peers
The company faces competitive risks related to intellectual property, including challenges in obtaining and maintaining patent rights and protecting trade secrets. It has acquired patents and related intellectual property from Xylo Technologies Ltd. for the MUSE™ system but faces risks such as patent expirations and the formal transfer of patents. In the pharmaceutical sector, competition may arise from other companies introducing new products more rapidly, particularly if the company is unable to utilize the FDA's Section 505(b)(2) regulatory pathway. Competitors may also obtain orphan drug exclusivity or marketing exclusivity for drugs containing the same active moiety, potentially limiting the company's commercialization efforts. Legal challenges to FDA regulations and exclusivity provisions could further affect competitive protections. Additionally, sharing trade secrets with third parties increases the risk of competitors accessing proprietary information, which may adversely impact the company's competitive position.
August 28, 2025
In a surprising turn of events, SciSparc Ltd. (Nasdaq: SPRC), traditionally a stalwart in the pharmaceutical sector focusing on central nervous system disorders, announced a monumental shift in its operational strategy with the approval of a merger with AutoMax Motors Ltd., a leading parallel vehicle importer in Israel. The decision, which was made during an adjourned special general meeting of shareholders on August 26, 2025, signifies a strategic pivot towards diversification, blending healthcare expertise with automotive innovation.Headquartered in Tel Aviv, SciSparc has been at the forefront of developing therapeutic solutions for a range of neurological disorders, driven by its commitment to enhance pat...
March 3, 2025
SciSparc Ltd. (Nasdaq: SPRC), an innovative clinical-stage pharmaceutical company dedicated to pioneering therapies for challenging central nervous system disorders, has been in the news for a series of significant strategic maneuvers aimed at strengthening its market position and broadening its operational sphere. These moves reflect a strategic pivot that might redefine its trajectory in the industry. Divestment from MitoCareX: Redefining Core Focus In a definitive agreement, SciSparc has decided to sell its shares in MitoCareX Bio, a company at the forefront of computational drug discovery targeting resistant cancers. This transaction will see SciSparc offloading its shares for $700,000 while also exchang...
September 18, 2024
SciSparc Ltd, a biopharmaceutical company focused on the development of cannabinoid-based therapies, has recently made significant progress by submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase IIb clinical trial aimed at investigating treatments for Tourette Syndrome. This trial will be conducted in collaboration with prestigious institutions including the Yale Child Study Center at Yale School of Medicine, Hannover Medical School in Germany, and the Tel Aviv Sourasky Medical Center in Israel. Alongside this milestone, SciSparc also reported its financial performance for the fourth quarter of 2023, showcasing a notable return on average inv...
March 12, 2024
In recent years, the pharmaceutical industry has witnessed impressive advancements in the development of innovative therapies to combat various disorders and rare diseases. SciSparc Ltd., a pioneering clinical-stage pharmaceutical company, is at the forefront of this transformative wave. Their relentless dedication to research and development has revolutionized cancer treatment, pain management, and the clinical trial process for Autism Spectrum Disorder (ASD). This article aims to provide an in-depth analysis of SciSparc s groundbreaking discoveries and their potential impact on current medical practices.Cancer Treatment Breakthrough: MitoCareX Reveals Promising ResultsMitoCareX Bio, a subsidiary of SciSpar...
December 7, 2023
SciSparc Announces Acquisition of Leading Vehicle Importer in Israel and Revised Ownership Structure TEL AVIV, Israel, Dec. 07, 2023 - SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on developing therapies for central nervous system disorders and rare diseases, has provided updates on the negotiation process following the signing of a non-binding letter of intent (LOI) with a prominent vehicle importer company in Israel, referred to as the Target Company, on November 22, 2023. The company has now revealed that it will acquire 100% of the Target Company and establish a new wholly-owned Israeli subsidiary, which will subsequently merge with and into the Target Comp...
November 24, 2023
New Hope for Children: SciSparc s CBD-Enhanced Solution for Autism Spectrum Disorder Shows Promising Results TEL AVIV, Israel, Nov. 24, 2023 - SciSparc Ltd. (Nasdaq: SPRC), a leading specialty clinical-stage pharmaceutical company in the central nervous system disorders and rare diseases sector, recently announced the initiation of a clinical trial for its revolutionary therapy, SCI-210, designed to address the symptoms of Autism Spectrum Disorder (ASD) in children. This groundbreaking approach, utilizing SciSparc s proprietary CBD-enhanced solution, holds tremendous potential for transforming the lives of those affected by this complex neurodevelopmental condition. The clinical trial, conducted at S...
Praxis Precision Medicines Inc's business model revolves around developing precision medicines for the treatment of various central nervous system (CNS) disorders.
Quoin Pharmaceuticals Ltd operates on a direct-to-consumer (DTC) business model by developing and manufacturing pharmaceutical products for individual customers. The company focuses on creating specialized medicines tailored to meet the unique healthcare needs of patients. Quoin Pharmaceuticals aims to establish a close relationship with consumers, providing high-quality and personalized medications while bypassing traditional intermediaries in the pharmaceutical industry.
Arcus Biosciences Inc is a biotechnology company that focuses on developing immuno-oncology therapies. Their business model revolves around discovering and developing novel small molecule and antibody therapeutics to target various cancer indications. They aim to combine their extensive understanding of the immune system with innovative technology platforms to create effective treatments for patients with cancer.
Regen Biopharma Inc is a biotechnology company that focuses on developing innovative treatments for diseases like cancer and autoimmune disorders. Their business model revolves around conducting research and development activities to create novel therapeutics and licensing or partnering with larger pharmaceutical companies for further development and commercialization. By leveraging their scientific expertise and strategic collaborations, Regen Biopharma aims to bring cutting-edge medical solutions to the market and improve patient outcomes.
Sources:
Scisparc Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Scisparc Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
